Glioblastoma Peptide Vaccine Roundup: Real-World Personalized Vaccine Outcomes + UCPVax 26% 2-Year OS in Phase I/II
Recent reviews and real-world observation studies aggregate the state of peptide-vaccine immunotherapy for glioblastoma. A 2024 Nature Communications real-world observational study reported clinically meaningful outcomes for personalized peptide vaccines; the UCPVax + temozolomide trial (NCT04280848) showed 97% anti-TERT immune response, 48% epitope spread, median OS 17.9 months, and 26% alive at 2 years. The peptide-vaccine modality is one of multiple approaches (mRNA, dendritic cell, neoantigen) advancing alongside immune checkpoint blockade.